AXL and renal cell carcinoma: Cabozantinib is a TKI that targets the VEGF receptor and inhibits expression of the MET and AXL genes, which are associated with resistance to VEGF molecular pathway inhibitors and poor prognosis in RCC patients (Choueiri et al. 2014).